endless round of pretrial jockeying-nothing to worry about

New Post Public Reply Private Reply Replies (0) Message Board
microcaps
endless round of pretrial jockeying-nothing to worry about

CWRN's attorney argues and moved to quash Geos attempt to depose Bob again because notice was not received til sept 20 and 30 days notice is required for production of docs at a deposition-which Geo is asking for in a tremendous fishing exposition--

1 reason,in addition to the normal delays in financials for essentially all these pennies we think Brad may be delaying financials etc until tx games are over, and noting bob had already been deposed aug 2 at same time geo had noted a depo for shirley,but geo had not deposed shirley at that time despite shirley being present at great personal travel etc expense
and arguing the time for discovery had passed

these things are not really helpful news because they are just endless pre-trial jockeying- when judgment is made that will be news - and remember again CWRN has a much bigger case against Geo in CA where the whole thing should've been heard as per the JVA imo-

and cwrn is waiting for the Ca case to present the vast majority of its case in 13 counts-
the Tx case seems to be mostly limited to who owns certain pieces of equipment-and Geo keeps changing its story re which equipment it claims- as per the jva the concession is cwrns and I believe the equipment-Geo is not asking for equip anymore but a monetary value for such-but  cwrn claims geo withheld millions from the 1st 2 ships,which cwrn needed for equipment and to pay for next ship etc-resulting in stop and go shipping due to the alleged withheld millions of receipts needed to keep ships running on a revolving basis

Cotton & Western Mining Inc. (CWRN) Stock Research Links

CWRN Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Triumph Financial Sets Stage for Q4 Earnings and Insights

Updated Category News Views 196

Triumph Financial Plans Fourth Quarter Earnings Release Triumph Financial, Inc. (Nasdaq: TFIN) recently announced its anticipation for the release of fourth quarter financial results. This event is scheduled to take place after the market closes on an upcoming Wednesday. Along with the financial report, the company will provide management commentary for stakeholders and...

Continue Reading
Monitoring ABA Therapy Progress: A Parent's Guide

Updated Category News Views 6

The Nuts and Bolts of Progress Monitoring You've got a situation in Leominster where parents are trying to make sense of ABA therapy's impact on their kids. Rob Shapiro, a big name in the ABA world, breaks it all down in a HelloNation article. We're talking about precise data collection being the backbone of measuring progress in ABA therapy. This ain't no place for...

Continue Reading
Understanding Dowlais Group's Recent Market Activities

Updated Category News Views 185

Public Disclosure Regarding Dowlais Group's Trading Activity FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code 1. KEY INFORMATION (a) Name of exempt principal trader: Investec Bank plc (b) Name of offeror/offeree in relation to whose r

Continue Reading
OFS Credit Company Reports Impressive Q4 Financials for 2024

Updated Category News Views 98

OFS Credit Company Delivers Strong Q4 2024 Financial Results OFS Credit Company, Inc. (NASDAQ: OCCI), a notable investment firm focusing on collateralized loan obligation (CLO) equity and debt securities, has announced its financial performance for the fiscal quarter ending October 31, 2024. This report outlines the company’s significant financial growth and strategic...

Continue Reading
Breakthrough Data on HBI-8000 and Nivolumab for Melanoma

Updated Category News Views 89

HBI-8000 and Nivolumab: A New Era in Melanoma Treatment Recent findings highlight the potential of HBI-8000 in combination with nivolumab, suggesting a transformative approach in the treatment of advanced melanoma. This promising combination will be discussed in detail at an upcoming prestigious annual meeting focused on advancements in immunotherapy. Innovative Solutions...

Continue Reading